| __timestamp | Axsome Therapeutics, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 7461000 |
| Thursday, January 1, 2015 | 2419289 | 11960000 |
| Friday, January 1, 2016 | 6343648 | 13108000 |
| Sunday, January 1, 2017 | 7206691 | 17501000 |
| Monday, January 1, 2018 | 9351522 | 22472000 |
| Tuesday, January 1, 2019 | 13598030 | 24286000 |
| Wednesday, January 1, 2020 | 28896749 | 29689000 |
| Friday, January 1, 2021 | 66646205 | 38837000 |
| Saturday, January 1, 2022 | 159253661 | 47489000 |
| Sunday, January 1, 2023 | 323123000 | 53379000 |
Unleashing insights
In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and profitability. Over the past decade, Axsome Therapeutics, Inc. and Xencor, Inc. have demonstrated contrasting approaches to handling these costs. From 2014 to 2023, Axsome's SG&A expenses surged by over 23,000%, peaking at $323 million in 2023. In contrast, Xencor's expenses grew by approximately 615%, reaching $53 million in the same year.
While Axsome's aggressive spending reflects its rapid expansion and investment in new therapies, Xencor's more conservative approach suggests a focus on maintaining operational efficiency. This divergence highlights the strategic choices companies face in balancing cost management with growth ambitions. As the biotech sector continues to evolve, these insights offer valuable lessons for investors and industry leaders alike.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
argenx SE and Xencor, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Axsome Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Axsome Therapeutics, Inc. or Verona Pharma plc: Who Manages SG&A Costs Better?
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Novavax, Inc.
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Xencor, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.